Inosiplex (Inosine Pranobex) - Pediatric Indications and Dosage
Based on available FDA labeling, Inosiplex lacks established pediatric indications and standardized dosing in the United States, as it is marketed as a homeopathic product without FDA evaluation for efficacy. 1
Current Regulatory Status
The FDA-labeled product available in the U.S. is classified as a homeopathic preparation with the following characteristics:
- Claims: Based on traditional homeopathic practice, not accepted medical evidence 1
- FDA Status: Not FDA evaluated 1
- Labeled Use: "Promotes healthy balance of homologous organs" - a non-specific homeopathic claim 1
- Administration: Oral use only 1
Evidence from Clinical Research
While the drug lacks FDA approval for specific indications, international research provides context on its use:
Dosing Used in Research Studies:
- Standard pediatric dose: 50 mg/kg/day divided into 3-4 doses 2, 3
- Maximum daily dose: Up to 4 g/day 4
- Duration: Typically 7-14 days for acute infections 3, 4
Studied Indications (Not FDA-Approved):
- Acute respiratory viral infections - particularly in children with comorbidities and suspected immune dysregulation 3
- Recurrent respiratory infections - though a controlled trial showed no benefit 2
- Various viral infections - including herpes viruses, HPV, and respiratory viruses 5, 6
Critical Clinical Caveats
The evidence is contradictory and insufficient for routine use:
- A 1999 placebo-controlled trial in 102 children (ages 4-8) found no benefit in preventing recurrent respiratory infections despite transient increases in T-lymphocyte counts 2
- A 2025 case series showed clinical improvement in 14 children with complex ARIs and comorbidities, but this was observational without controls 3
- Most positive data comes from adult COVID-19 studies 4
Important warnings from FDA labeling:
- Do not use if allergic to any ingredient 1
- Consult a doctor before use for serious conditions 1
- Consult a doctor if pregnant or nursing 1
Clinical Recommendation
In the United States, Inosiplex cannot be recommended for any specific pediatric indication due to lack of FDA approval and conflicting evidence. If considering use based on international practice patterns, the research-based dosing would be 50 mg/kg/day divided into 3-4 doses (maximum 4 g/day) for 7-14 days, but this should only occur in consultation with specialists and with clear informed consent about the lack of regulatory approval and mixed evidence base.
For children with recurrent respiratory infections, focus on evidence-based interventions rather than immunomodulators with unproven benefit 2.